Why Russia Is Ahead of the Game on Cognitive Peptides

While Western pharmaceutical markets focus heavily on GLP-1 agonists and monoclonal antibodies, Russia has quietly built one of the most advanced regulatory frameworks for peptide-based cognitive drugs in the world. Several compounds that remain "research-only" in the US, UK, and EU have been prescribed by Russian physicians for decades, backed by a clinical literature, much of it small studies published in Russian, that has not led to Western approvals.

The Russian Peptide Tradition

Russia's head start traces back to the Soviet-era Institute of Molecular Genetics and the Military Medical Academy in St. Petersburg. In the 1980s and 1990s, Soviet researchers (particularly Professor Nikolai Myasoedov at the Russian Academy of Sciences and Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology) began systematically developing synthetic peptide analogues of natural regulatory molecules.

The result was a generation of peptide drugs that passed through Russia's regulatory system (overseen by the Ministry of Health) and entered clinical practice years before Western researchers even began investigating them seriously.

Approved Cognitive Peptides in Russia

Here are the key compounds. The first five are approved medicines in Russia that remain unapproved in the US and UK; the sixth, Pinealon, is sold in Russia as a dietary supplement:

1. Semax (ACTH 4-10 Analogue)

• Approved in Russia: used clinically there in stroke and other cerebrovascular disease
• Mechanism: Synthetic analogue of ACTH(4-10) with a Pro-Gly-Pro tripeptide extension. In rats it raised BDNF (brain-derived neurotrophic factor) and TrkB receptor activity in the hippocampus (Dolotov et al., 2006) and switched on neurotrophin genes, including NGF, after experimental stroke (Dmitrieva et al., 2010)
• Key research: Small Russian clinical studies in ischaemic stroke reported faster recovery of neurological, especially motor, function (30 treated patients compared with 80 on standard therapy; Gusev et al., 1997) and higher blood BDNF with better daily-living scores during rehabilitation (110 patients; Gusev et al., 2018); a study of 187 patients with chronic cerebrovascular insufficiency also reported clinical improvement (Gusev et al., 2005). In rats with experimental stroke, a genome-wide study at the Institute of Molecular Genetics found Semax mainly changed the activity of immune-response genes, along with 24 vascular-system genes three hours after the stroke (Medvedeva et al., 2014)
• Western status: Not FDA-approved, not EMA-approved. Available only as a research chemical

2. Selank (Tuftsin Analogue)

• Approved in Russia: as an anti-anxiety medicine
• Mechanism: Synthetic analogue of the immunomodulatory peptide tuftsin, with a Pro-Gly-Pro stabilising sequence. Rat studies suggest effects on the GABA system (Volkova et al., 2016). It inhibits the enzymes that break down enkephalins in human blood plasma (Zozulya et al., 2001) and suppressed IL-6 gene expression in blood cells from patients with depression in vitro (Uchakina et al., 2008)
• Key research: A Russian study of 62 patients with generalised anxiety disorder or neurasthenia found anxiolytic effects similar to the benzodiazepine medazepam, with additional anti-asthenic and stimulant effects for Selank (Zozulia et al., 2008)
• Western status: Not FDA-approved, not EMA-approved. Research compound only

3. Noopept (N-Phenylacetyl-L-Prolylglycine Ethyl Ester)

• Approved in Russia: a prescription medicine there for traumatic brain injury, mood disorders and cerebrovascular disease (Vanhee et al., 2025)
• Mechanism: Dipeptide-derived compound that crosses the blood-brain barrier. In rats it increased NGF and BDNF expression in the hippocampus (Ostrovskaya et al., 2008), and in rat brain tissue it bound weakly to AMPA glutamate receptor sites (Firstova et al., 2011)
• Key research: A Russian clinical study compared Noopept with piracetam in patients with mild cognitive disorders after vascular or traumatic brain disease (Neznamov and Teleshova, 2009); no abstract is available on PubMed to check its results
• Western status: Not FDA-approved and not authorised in the EU (Vanhee et al., 2025). Sold as a dietary supplement in some markets, research chemical in others

4. Cortexin

• Approved in Russia: prescribed for stroke rehabilitation, traumatic brain injury (TBI), epilepsy, and encephalopathy in both adults and children
• Mechanism: A lyophilised preparation of polypeptides from cattle (bovine) cerebral cortex (Kurkin et al., 2025). Described as a multi-target neuroprotective agent
• Key research: Numerous studies in Russian journals, mostly small. In a 90-patient stroke study, a repeated course was followed by more complete regression of neurological deficit (Belova et al., 2016), and a study of 86 children and adolescents with epilepsy reported improved EEG measures (Kalmykova et al., 2021)
• Western status: Not FDA-approved, not EMA-approved. Not widely available outside Russia and CIS countries

5. Cerebrolysin

• Approved in Russia and 45+ countries: Prescribed for Alzheimer's disease, vascular dementia, stroke recovery, and TBI (but notably not approved in the US or UK)
• Mechanism: A peptide preparation made by controlled digestion of pig brain proteins. Cell and animal studies report effects resembling the body's own neurotrophic factors (Masliah and Díez-Tejedor, 2012), but a mass spectrometry analysis found no fragments of known neurotrophic factors such as GDNF, NGF, BDNF or CNTF in it (Gevaert et al., 2015)
• Key research: Randomised trials in stroke. CASTA, with 1,070 patients, found no difference on its primary outcome, with a possible benefit in severe strokes in a post hoc analysis (Heiss et al., 2012); the smaller, exploratory CARS trial reported better arm function during early rehabilitation (Muresanu et al., 2016). Cochrane reviews are cautious: in acute ischaemic stroke it probably does not reduce deaths and may increase non-fatal serious adverse events (Ziganshina et al., 2023), and in vascular dementia trials reported better cognition but carried a high risk of bias, with any effect possibly too small to matter clinically (Cui et al., 2019)
• Western status: Approved in over 45 countries across Asia, Europe, and Latin America, but not FDA-approved and not MHRA-approved

6. Pinealon

• Developed in Russia: Part of the Khavinson peptide bioregulator series from the St. Petersburg Institute of Bioregulation and Gerontology
• Mechanism: Short tripeptide (Glu-Asp-Arg) that targets brain tissue. Proposed to regulate gene expression in neurons and protect against oxidative stress; in cell cultures it limited the build-up of reactive oxygen species and reduced cell death (Khavinson et al., 2011)
• Key research: Mostly cell and animal studies. Human data are limited to small Russian studies, such as one of 32 adults aged 41 to 83 with organic brain syndrome that reported changes in biological-age markers (Meshchaninov et al., 2015)
• Western status: Research compound only. Not an approved medicine: in Russia it is registered as a dietary supplement (RLS register entry)

Why Is Russia Ahead?

Different Regulatory Philosophy

The Russian Ministry of Health has historically taken a more pragmatic approach to peptide therapeutics. While the FDA and EMA expect multi-phase, placebo-controlled, double-blind trials that take many years and, on one widely cited estimate, cost billions of dollars per approved drug (DiMasi et al., 2016), the published clinical evidence behind these Russian approvals comes largely from smaller studies, many of them in Russian-language journals.

Institutional Investment

Russia invested heavily in peptide research through state institutions, the Russian Academy of Sciences, the Institute of Molecular Genetics, and the Military Medical Academy. This wasn't driven by private pharmaceutical profit motives but by state-funded research into cognitive performance, cellular senescence, and military readiness.

No Patent Incentive Problem

Many of these peptides are short sequences, 3 to 7 amino acids, which may be harder to protect commercially in Western markets. Without strong patent protection, Western pharmaceutical companies have little financial incentive to fund the expensive trials needed for FDA or EMA approval. Russia's state-funded model bypassed this commercial barrier entirely.

Decades of Clinical Data

Compounds like Semax have been in clinical use in Russia for decades. This real-world experience is a substantial body of evidence, but it is not structured to Western clinical trial standards, and independent validation and systematic safety surveillance are still lacking (Mavrych et al., 2026).

Comparison Table: Russian-Approved vs Western Status

What This Means for Researchers

Russia's peptide pharmacopoeia represents a largely untapped resource for Western researchers. The clinical data exists, much of it published in Russian-language journals and indexed in databases like eLibrary.ru and CyberLeninka. As Western interest in peptide therapeutics accelerates (driven by the GLP-1 boom), expect increased attention on these cognitive compounds.

For researchers interested in cognitive peptides, the Russian experience offers both a roadmap and a cautionary tale: these compounds are used in clinical practice there, but bridging the gap to Western regulatory approval requires investment that the current patent system doesn't incentivise.

Key Takeaways

• Russia has approved 5+ cognitive peptide drugs that remain unapproved in the US and UK
• Semax, Selank, and Noopept have mechanism studies, mostly in rats, involving BDNF, NGF, and the GABA system
• The regulatory gap reflects patent economics and differing clinical trial standards, and much of the Russian clinical evidence comes from small studies
• Cerebrolysin is the closest to Western acceptance, approved in 45+ countries but not approved by the FDA or MHRA, and Cochrane reviews rate its evidence cautiously
• Decades of real-world prescribing in Russia provide a large body of experience, though independent validation and systematic safety surveillance are lacking

References

1. Belova LA, et al. (2016). [Efficacy of cortexin in acute and recovery periodes of hemispheric ischemic stroke]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed 27845314
2. Cui S, et al. (2019). Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. PubMed 31710397
3. DiMasi JA, et al. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. PubMed 26928437
4. Dmitrieva VG, et al. (2010). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology. PubMed 19633950
5. Dolotov OV, et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. PubMed 16996037
6. Firstova IuIu, et al. (2011). [Studying specific effects of nootropic drugs on glutamate receptors in the rat brain]. Eksperimental'naia i Klinicheskaia Farmakologiia. PubMed 21476267
7. Gevaert B, et al. (2015). Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry. Drug Testing and Analysis. PubMed 26017115
8. Gusev EI, et al. (1997). [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed 11517472
9. Gusev EI, et al. (2005). [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed 15792140
10. Gusev EI, et al. (2018). [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed 29798983
11. Heiss WD, et al. (2012). Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. PubMed 22282884
12. Kalmykova GV, et al. (2021). [Cortexin administration due to improvement of cognitive and behavioral disorders in children and teenagers with epilepsy]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed 33834730
13. Khavinson V, et al. (2011). Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research. PubMed 21978084
14. Kurkin DV, et al. (2025). Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay. Biomedicines. PubMed 40299434
15. Masliah E, Díez-Tejedor E. (2012). The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs of Today. PubMed 22514792
16. Mavrych V, et al. (2026). Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in Aging. PubMed 42021992
17. Medvedeva EV, et al. (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. PubMed 24661604
18. Meshchaninov VN, et al. (2015). [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]. Advances in Gerontology. PubMed 26390612
19. Muresanu DF, et al. (2016). Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. PubMed 26564102
20. Neznamov GG, Teleshova ES. (2009). Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neuroscience and Behavioral Physiology. PubMed 19234797
21. Ostrovskaya RU, et al. (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bulletin of Experimental Biology and Medicine. PubMed 19240853
22. Uchakina ON, et al. (2008). [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed 18577961
23. Vanhee C, et al. (2025). The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories. Journal of Xenobiotics. PubMed 40558871
24. Volkova A, et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. PubMed 26924987
25. Ziganshina LE, et al. (2023). Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. PubMed 37818733
26. Zozulia AA, et al. (2008). [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed 18454096
27. Zozulya AA, et al. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. PubMed 11550013